Tag: Transplant Rejection
Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration
AUSTIN, Texas and BARCELONA, Spain, Feb. 15, 2022 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.
Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection
AUSTIN, Texas and LOOS, France, March 24, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC).
Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens in Transplant Rejection
AUSTIN, Texas and EVANSTON, Ill., March 17, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Northwestern University, a world leader in HLA DQ antigen research.
Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration
AUSTIN, Texas and BASEL, Switzerland, Jan. 27, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The Transplantation Immunology & Nephrology Department of the University Hospital of Basel.
